

Special Issue

Epidrugs: Toward Understanding and Treating Diverse Diseases

Message from the Guest Editor

Epigenomic modifications are unique in that the type and amount of chemical modification at each chromosomal location can vary from cell to cell. In recent years, not only have these epigenomic modifications been revealed genome-wide, but rapid progress has also been made in the identification of the proteins responsible for epigenomic modifications and the development of their regulatory compounds. This Special Issue on "Epidrugs" aims to provide insights into broad aspects of biology and drug development through epigenome-regulating compounds.

Guest Editor

Dr. Takashi Umehara

Drug Discovery Structural Biology Platform Unit, RIKEN Center for Biosystems Dynamics Research, 1-7-22 Suehiro, Tsurumi, Yokohama 230-0045, Japan

Deadline for manuscript submissions

closed (31 May 2023)



Epigenomes

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 4.4
Indexed in PubMed



mdpi.com/si/127862

Epigenomes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
epigenomes@mdpi.com

[mdpi.com/journal/
epigenomes](https://mdpi.com/journal/epigenomes)





Epigenomes

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 4.4
Indexed in PubMed



[mdpi.com/journal/
epigenomes](https://mdpi.com/journal/epigenomes)



About the Journal

Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

Epigenomes (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Editor-in-Chief

Prof. Dr. Ernesto Guccione

Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine, New York, NY 10029, USA

Author Benefits

High Visibility:

indexed within Scopus, ESCI (Web of Science), PMC, PubMed, Embase, PubAg, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Biochemistry, Genetics and Molecular Biology (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 20.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).